Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Ipilimumab + Melphalan ILI for In-transit Melanoma
NCT02115243Phase 1Completed
- Sponsor
- Duke University
- Start
- May 2014
- Primary completion
- Dec 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ipilimumab in melanoma, sponsored by Duke University. Primary endpoint: Safety and tolerability at 2 years. Started May 2014; status: completed.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02115243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02115243.